Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082204 | 0.84 | TRPV1 (0.59) | HDAC1HDAC2TRPV1 | |
| SCHEMBL1060598 | 0.83 | HDAC1 (0.79) | HDAC1HDAC2HDAC3MAPK1HDAC4 | |
| SCHEMBL12841849 | 0.83 | HDAC1 (0.76) | HDAC1HDAC2HDAC3MAPK1HDAC4 | |
| SCHEMBL14082273 | 0.83 | RAB9A (0.72) | TRPV1 | |
| SCHEMBL14082220 | 0.83 | NPC1 (0.61) | TRPV1 | |
| SCHEMBL8401704 | 0.82 | HDAC1 (0.89) | HDAC1HDAC2HDAC3MAPK1HDAC4 | |
| SCHEMBL2828709 | 0.81 | HDAC2 (0.72) | HDAC1HDAC2HDAC3MAPK1HDAC4 | |
| SCHEMBL30864183 | 0.81 | HDAC2 (0.72) | HDAC1HDAC2HDAC3MAPK1HDAC4 | |
| SCHEMBL14108040 | 0.80 | PTGS1 (0.67) | HDAC1HDAC2HDAC3MAPK1HDAC4 | |
| SCHEMBL14082213 | 0.80 | MAPT (0.61) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | disclosed |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-03-25 | — | — | US | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| CN-101052620-A | Benzamide compound | ASTRAZENECA AB (SE) | 2007-10-10 | — | — | CN | disclosed |
| WO-2007071961-A1 | BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071956-A1 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006075160-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | HDAC1 556/4885HDAC2 660/4885HDAC3 324/4885 |
| US-20100075942-A1 | N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC2 2/4885HDAC3 3/4885 |
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC2 3/4885HDAC3 5/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | HDAC1 1/4885HDAC2 3/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.